Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asahi Chemical Trains Apheresis Specialists For Chinese Hospitals

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based medical device maker Asahi Chemical Kuraray Medical established the Apheresis Training Center in Beijing. In collaboration with Captial Medical University's Youan Hospital, Asahi Chemical will use the center to train physicians and nurses for apheresis and dialysis treatments in Chinese hospitals. Youan Hospital has used apheresis to treat over 18,000 patients with liver disease, and apheresis is gaining popularity in China as a key treatment for patients with multi-organ failure, liver failure and intractable autoimmune disorders. The company also plans to launch satellite training centers in other major Chinese cities such as Shanghai and Guangzhou. Asahi also looks to establish similar training facilities in the U.S. and Canada. (Click here for more - Japanese language

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

UsernamePublicRestriction

Register

SC072294

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel